175 related articles for article (PubMed ID: 26927669)
21. Key role of suppressor of cytokine signaling 3 in regulating gp130 cytokine-induced signaling and limiting chondrocyte responses during murine inflammatory arthritis.
Liu X; Croker BA; Campbell IK; Gauci SJ; Alexander WS; Tonkin BA; Walsh NC; Linossi EM; Nicholson SE; Lawlor KE; Wicks IP
Arthritis Rheumatol; 2014 Sep; 66(9):2391-402. PubMed ID: 24839265
[TBL] [Abstract][Full Text] [Related]
22. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes.
Krejci P; Prochazkova J; Bryja V; Jelinkova P; Pejchalova K; Kozubik A; Thompson LM; Wilcox WR
Cell Signal; 2009 Jan; 21(1):151-60. PubMed ID: 18950705
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid-induced impairment of mammary gland involution is associated with STAT5 and STAT3 signaling modulation.
Bertucci PY; Quaglino A; Pozzi AG; Kordon EC; Pecci A
Endocrinology; 2010 Dec; 151(12):5730-40. PubMed ID: 20881248
[TBL] [Abstract][Full Text] [Related]
25. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation.
Gu Z; Wang H; Xia J; Yang Y; Jin Z; Xu H; Shi J; De Domenico I; Tricot G; Zhan F
Cancer Res; 2015 Jun; 75(11):2211-21. PubMed ID: 25855377
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis.
Setsu N; Kohashi K; Endo M; Yamamoto H; Tamiya S; Takahashi Y; Yamada Y; Ishii T; Matsuda S; Yokoyama R; Iwamoto Y; Oda Y
Int J Cancer; 2013 Jan; 132(1):109-15. PubMed ID: 22644781
[TBL] [Abstract][Full Text] [Related]
27. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.
Bollrath J; Phesse TJ; von Burstin VA; Putoczki T; Bennecke M; Bateman T; Nebelsiek T; Lundgren-May T; Canli O; Schwitalla S; Matthews V; Schmid RM; Kirchner T; Arkan MC; Ernst M; Greten FR
Cancer Cell; 2009 Feb; 15(2):91-102. PubMed ID: 19185844
[TBL] [Abstract][Full Text] [Related]
28. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.
Nishihara M; Ogura H; Ueda N; Tsuruoka M; Kitabayashi C; Tsuji F; Aono H; Ishihara K; Huseby E; Betz UA; Murakami M; Hirano T
Int Immunol; 2007 Jun; 19(6):695-702. PubMed ID: 17493959
[TBL] [Abstract][Full Text] [Related]
29. SOCS3 negatively regulates the gp130-STAT3 pathway in mouse skin wound healing.
Zhu BM; Ishida Y; Robinson GW; Pacher-Zavisin M; Yoshimura A; Murphy PM; Hennighausen L
J Invest Dermatol; 2008 Jul; 128(7):1821-9. PubMed ID: 18185532
[TBL] [Abstract][Full Text] [Related]
30. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model.
Hatting M; Spannbauer M; Peng J; Al Masaoudi M; Sellge G; Nevzorova YA; Gassler N; Liedtke C; Cubero FJ; Trautwein C
Cell Death Dis; 2015 Mar; 6(3):e1667. PubMed ID: 25741592
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
32. Involvement of gp130-associated cytokine signaling in Müller cell activation following optic nerve lesion.
Kirsch M; Trautmann N; Ernst M; Hofmann HD
Glia; 2010 May; 58(7):768-79. PubMed ID: 20091786
[TBL] [Abstract][Full Text] [Related]
33. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 11 signaling components signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) regulate human endometrial stromal cell differentiation.
Dimitriadis E; Stoikos C; Tan YL; Salamonsen LA
Endocrinology; 2006 Aug; 147(8):3809-17. PubMed ID: 16709613
[TBL] [Abstract][Full Text] [Related]
35. Novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) stimulates corticotroph function via a signal transducer and activator of transcription-dependent mechanism negatively regulated by suppressor of cytokine signaling-3.
Auernhammer CJ; Isele NB; Kopp FB; Spoettl G; Cengic N; Weber MM; Senaldi G; Engelhardt D
Endocrinology; 2003 Apr; 144(4):1202-10. PubMed ID: 12639901
[TBL] [Abstract][Full Text] [Related]
36. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.
Gallardo M; Lee HJ; Zhang X; Bueso-Ramos C; Pageon LR; McArthur M; Multani A; Nazha A; Manshouri T; Parker-Thornburg J; Rapado I; Quintas-Cardama A; Kornblau SM; Martinez-Lopez J; Post SM
Cancer Cell; 2015 Oct; 28(4):486-499. PubMed ID: 26412324
[TBL] [Abstract][Full Text] [Related]
37. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis.
Fischer P; Hilfiker-Kleiner D
Basic Res Cardiol; 2007 Jul; 102(4):279-97. PubMed ID: 17530315
[TBL] [Abstract][Full Text] [Related]
38. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma.
Iida S; Shimazaki C; Abe M; Nakaseko C
Int J Hematol; 2019 Jun; 109(6):633-640. PubMed ID: 30963472
[No Abstract] [Full Text] [Related]
39. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM).
Iida S; Ishida T; Murakami H; Ozaki S; Abe M; Hata H; Shimazaki C
Int J Hematol; 2019 May; 109(5):509-538. PubMed ID: 30949913
[No Abstract] [Full Text] [Related]
40. Molecular Immunology in Hematological Disorders.
Takami A
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
